Biovail has agreed to acquire worldwide development and marketing rights to the entire portfolio of tetrabenazine drugs from Cambridge Laboratories for $230m.

Biovail will acquire the drugs used in the treatment of chorea (a symptom of Huntington’s disease) to focus on treating disorders of the central nervous system (CNS).

In 2008, the company made its first foray into the CNS disorder speciality market by acquiring Canadian and US licensing rights to the drug Xenazine, through purchasing Prestwick Pharmaceuticals.

Biovail CEO Bill Wells said that the acquisition would immediately be accretive to revenues, margins and operating cash flows, and is anticipated to be moderately accretive to GAAP earnings per share in 2010.

To complete the present deal, Biovail will also pay another $30m in two tranches over the next two years. The acquisition, as per the company, includes a controlled-release formulation of tetrabenazine in development for Tourette syndrome, as well as a tetrabenazine-derived new chemical entity that may enter mid-stage clinical development in the next one year.

Following the acquisition, Biovail will gain a broad range of intellectual property rights for the product portfolio.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.